Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $43.25M.
ENTERPRISE VALUE (EV)
$43.25M
Acrivon Therapeutics, Inc. Common Stock
Market Cap
$84.75M
Enterprise Value (EV)
$43.25M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $84.75M | $43.25M |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | $91.35M |
| Humacyte, Inc. (HUMA)vs › | $84.00M | $70.28M |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | $50.46M |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | $127.30M |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | $79.12M |
| ImmuCell Corporation (ICCC)vs › | $88.21M | $91.79M |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | $74.87M |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | $55.93M |
Market Cap
$84.75M
Total Debt
$0.00
Cash
$41.50M
Enterprise Value
$43.25M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
